Immunocore (IMCR) Competitors $32.65 +0.04 (+0.12%) Closing price 04:00 PM EasternExtended Trading$32.62 -0.03 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. RYTM, RNA, NUVL, AXSM, CRSP, ABVX, MRUS, CYTK, VKTX, and TGTXShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Abivax (ABVX), Merus (MRUS), Cytokinetics (CYTK), Viking Therapeutics (VKTX), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Its Competitors Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Axsome Therapeutics CRISPR Therapeutics Abivax Merus Cytokinetics Viking Therapeutics TG Therapeutics Rhythm Pharmaceuticals (NASDAQ:RYTM) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Do analysts recommend RYTM or IMCR? Rhythm Pharmaceuticals presently has a consensus target price of $101.57, suggesting a potential downside of 0.71%. Immunocore has a consensus target price of $56.89, suggesting a potential upside of 74.24%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has preferable valuation and earnings, RYTM or IMCR? Immunocore has higher revenue and earnings than Rhythm Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M52.22-$260.60M-$3.01-33.99Immunocore$310.20M5.30-$51.09M-$0.40-81.63 Which has more volatility and risk, RYTM or IMCR? Rhythm Pharmaceuticals has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Does the media refer more to RYTM or IMCR? In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Immunocore. MarketBeat recorded 16 mentions for Rhythm Pharmaceuticals and 5 mentions for Immunocore. Immunocore's average media sentiment score of 1.30 beat Rhythm Pharmaceuticals' score of 1.05 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of RYTM or IMCR? 84.5% of Immunocore shares are owned by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is RYTM or IMCR more profitable? Immunocore has a net margin of -5.70% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Immunocore's return on equity of -5.40% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-117.13% -1,831.43% -48.33% Immunocore -5.70%-5.40%-1.93% SummaryImmunocore beats Rhythm Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65B$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-81.6321.2230.8326.39Price / Sales5.30206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book4.238.0710.106.62Net Income-$51.09M-$54.08M$3.26B$265.42M7 Day Performance0.49%3.94%3.90%3.58%1 Month Performance-7.17%3.02%3.73%0.46%1 Year Performance-9.68%6.84%37.68%19.41% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore1.7666 of 5 stars$32.65+0.1%$56.89+74.2%-11.6%$1.65B$310.20M-81.63320Positive NewsAnalyst ForecastRYTMRhythm Pharmaceuticals3.5291 of 5 stars$98.09+0.5%$101.57+3.5%+102.4%$6.48B$130.13M-32.59140Positive NewsInsider TradeRNAAvidity Biosciences2.9682 of 5 stars$44.48-4.3%$67.00+50.6%+6.5%$5.98B$10.90M-12.49190Positive NewsNUVLNuvalent3.3695 of 5 stars$75.01-1.4%$119.60+59.4%-10.9%$5.48BN/A-15.3140News CoveragePositive NewsAXSMAxsome Therapeutics4.8238 of 5 stars$111.13+1.8%$178.00+60.2%+36.9%$5.45B$385.69M-21.92380News CoveragePositive NewsInsider TradeCRSPCRISPR Therapeutics3.53 of 5 stars$57.59-3.6%$71.60+24.3%+11.6%$5.43B$37.31M-10.61460Positive NewsABVXAbivax2.7278 of 5 stars$70.01-0.6%$92.33+31.9%+585.3%$5.32BN/A0.0061News CoveragePositive NewsAnalyst RevisionMRUSMerus2.3137 of 5 stars$66.00-1.9%$88.50+34.1%+26.2%$5.09B$36.13M-12.0037Positive NewsAnalyst ForecastCYTKCytokinetics3.6062 of 5 stars$38.95+0.7%$71.58+83.8%-33.1%$4.63B$18.47M-7.64250News CoveragePositive NewsVKTXViking Therapeutics3.9581 of 5 stars$42.09+5.1%$86.92+106.5%-60.3%$4.50BN/A-27.5120TGTXTG Therapeutics4.4113 of 5 stars$27.73-1.2%$46.25+66.8%+18.0%$4.46B$329M74.95290Positive News Related Companies and Tools Related Companies RYTM Competitors RNA Competitors NUVL Competitors AXSM Competitors CRSP Competitors ABVX Competitors MRUS Competitors CYTK Competitors VKTX Competitors TGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access